Literature DB >> 15478850

Appropriate strategies for testing and treating Helicobacter pylori in children: when and how?

Philip M Sherman1.   

Abstract

Helicobacter pylori infection is acquired primarily during childhood and carries a significant lifetime risk for morbidity. In developing countries, approximately 70% of children are infected with the bacterium by their 15th birthday. In the United States, the rate of H pylori infection among children varies widely--approximately 10% of all 10-year-olds are infected; however, this figure is substantially higher among populations of immigrant children and children born of recent immigrants to the United States. H pylori transmission is primarily "person-to-person" via fecal-oral, gastric-oral, or oral-oral routes, with evidence suggesting contaminated water as a potential source of infection. Risk factors for infection in childhood include an infected family member, having > or =2 siblings, crowded living conditions, lower socioeconomic means, and attendance at a daycare facility. The natural history of H pylori infection includes an increased lifetime risk for peptic ulcer and gastric adenocarcinoma or lymphoma. In children and adults who develop H pylori-related peptic ulcer, cure of the infection is associated with a <5% rate of ulcer recurrence. The ideal mode of H pylori detection among children is unclear--currently available serology and whole blood tests are unreliable, while the urea breath test and stool antigen tests have not been studied adequately. Children with confirmed H pylori-related peptic ulcer disease, iron-deficiency (sideropenic) anemia, or a first-degree relative with gastric cancer should be treated for the infection using 1 of 3 available 10- to 14-day triple therapy regimens recommended by the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15478850     DOI: 10.1016/j.amjmed.2004.07.015

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  8 in total

Review 1.  Consequences of Helicobacter pylori infection in children.

Authors:  Lucia Pacifico; Caterina Anania; John F Osborn; Flavia Ferraro; Claudio Chiesa
Journal:  World J Gastroenterol       Date:  2010-11-07       Impact factor: 5.742

2.  Helicobacter pylori and the birth cohort effect: evidence for stabilized colonization rates in childhood.

Authors:  Caroline M den Hoed; Anne J Vila; Ingrid L Holster; Guillermo I Perez-Perez; Martin J Blaser; Johan C de Jongste; Ernest J Kuipers
Journal:  Helicobacter       Date:  2011-10       Impact factor: 5.753

3.  Helicobacter pylori: prevalence and relationship with abdominal pain in school children in Makkah City, western Saudi Arabia.

Authors:  Abdulwahab M A Telmesani
Journal:  Saudi J Gastroenterol       Date:  2009-04       Impact factor: 2.485

4.  Influence of Helicobacter pylori infection on ghrelin levels in children.

Authors:  Zhao-Hui Deng; Bo Chu; Ya-Zhen Xu; Bin Zhang; Li-Rong Jiang
Journal:  World J Gastroenterol       Date:  2012-09-28       Impact factor: 5.742

5.  Low prevalence of Helicobacter pylori infection in Canadian children: a cross-sectional analysis.

Authors:  Idit Segal; Anthony Otley; Robert Issenman; David Armstrong; Victor Espinosa; Ruth Cawdron; Muhammad G Morshed; Kevan Jacobson
Journal:  Can J Gastroenterol       Date:  2008-05       Impact factor: 3.522

6.  Health implications of children in child care centres Part B: Injuries and infections.

Authors: 
Journal:  Paediatr Child Health       Date:  2009-01       Impact factor: 2.253

7.  Impact of Age, Gender, and Addition of Probiotics on Treatment Success for Helicobacter pylori in Children.

Authors:  Noam Weiner; Ron Shaoul
Journal:  Glob Pediatr Health       Date:  2015-10-07

8.  Risk for Colorectal Neoplasia in Patients With Helicobacter pylori Infection: A Systematic Review and Meta-analysis.

Authors:  Da Sol Choi; Seung In Seo; Woon Geon Shin; Chan Hyuk Park
Journal:  Clin Transl Gastroenterol       Date:  2020-02       Impact factor: 4.396

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.